4,021 reports of this reaction
3.8% of all PIMAVANSERIN TARTRATE reports
#4 most reported adverse reaction
PRODUCT DOSE OMISSION ISSUE is the #4 most commonly reported adverse reaction for PIMAVANSERIN TARTRATE, manufactured by Acadia Pharmaceuticals Inc.. There are 4,021 FDA adverse event reports linking PIMAVANSERIN TARTRATE to PRODUCT DOSE OMISSION ISSUE. This represents approximately 3.8% of all 106,130 adverse event reports for this drug.
PIMAVANSERIN TARTRATE has an overall safety score of 85 out of 100. Patients taking PIMAVANSERIN TARTRATE who experience product dose omission issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION ISSUE is moderately reported among PIMAVANSERIN TARTRATE users, representing a notable but not dominant share of adverse events.
In addition to product dose omission issue, the following adverse reactions have been reported for PIMAVANSERIN TARTRATE:
The following drugs have also been linked to product dose omission issue in FDA adverse event reports:
PRODUCT DOSE OMISSION ISSUE has been reported as an adverse event in 4,021 FDA reports for PIMAVANSERIN TARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION ISSUE accounts for approximately 3.8% of all adverse event reports for PIMAVANSERIN TARTRATE, making it a notable side effect.
If you experience product dose omission issue while taking PIMAVANSERIN TARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.